Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Versant Venture Management, LLC (CIK 1560009) reported $141.4M across 8 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: GLUE ($52.3M, 37.00%), IPSC ($27.5M, 19.44%), LENZ ($24.3M, 17.19%), JBIO ($21.4M, 15.16%), CTNM ($7.1M, 5.01%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics, Inc. | $52.3M | 37.00% | 3.2M | Trimmed |
| 2 | IPSC | Century Therapeutics, Inc. | $27.5M | 19.44% | 12.2M | New |
| 3 | LENZ | Lenz Therapeutics, Inc. | $24.3M | 17.19% | 2.7M | Hold |
| 4 | JBIO | Jade Biosciences, Inc. | $21.4M | 15.16% | 1.5M | Hold |
| 5 | CTNM | Contineum Therapeutics, Inc. | $7.1M | 5.01% | 542,628 | Hold |
| 6 | CRSP | CRISPR Therapeutics AG | $7.1M | 5.01% | 148,831 | Hold |
| 7 | SKYE | Skye Bioscience, Inc. | $1.2M | 0.87% | 2.0M | Hold |
| 8 | TPST | Tempest Therapeutics, Inc. | $442,426 | 0.31% | 269,772 | Hold |
Source: SEC Form 13F filings · as of 2026-03-31